EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Community-acquired urinary tract infections in Southern Spain: epidemiology, antimicrobial resistance, and the emerging impact of SGLT2 inhibitors

Francisco Ruiz-Ruiz, Palma Lobo-Fernández, Aurora Vivancos-Caro, María del Rocío Fernández-Ojeda, Victoria Ruiz-Romero, Antonio Fernández-Moyano, Luis Gómez-Morales, Estefanía García-Sánchez

PeerJ · 20.11.2026 · 14 · e21738

DOI: 10.7717/peerj.21738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, online erschienen am 20.11.2026. Verfasst von Francisco Ruiz-Ruiz und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increasing antimicrobial resistance complicates community-acquired urinary tract infection (UTI) management. Moreover, the impact of emerging treatments like sodium-glucose cotransporter-2 (SGLT2) inhibitors on urinary ecology remains underexplored. This study analyzes microbiological profiles, resistance patterns, and the influence of SGLT2 inhibitors in a Primary Care setting in Southern Spain.

Methods

We conducted a retrospective observational study of community-acquired UTI in adult patients during 2022. Variables analyzed included isolated microorganisms, antimicrobial susceptibility, and clinical factors such as diabetes, functional dependence, and prior antibiotic or SGLT2 inhibitor use. Patients under 18 years of age and polymicrobial contamination (three or more isolates) were excluded to ensure a homogeneous sample to ensure a homogeneous sample of community-acquired monobacterial infections.

Results

A total of 489 positive urine cultures were analyzed (89.3% women; 71.2% > 51 years). Escherichia coli remained the predominant pathogen (64.4%), followed by Klebsiella pneumoniae (17.7%). Resistance rates for E. coli were high for ampicillin (62.3%) and ciprofloxacin (28.4%) but remained low for phosphomycin (1.9%) and nitrofurantoin (1.9%). Notably, in unadjusted analyses, patients treated with SGLT2 inhibitors showed a higher prevalence of K. pneumoniae (7.7% vs 2.5%; p = 0.024); however, this association did not remain statistically significant after multivariable adjustment (adjusted odds ratio (OR) 2.20; 95% confidence interval (CI) [0.72–6.43]; p = 0.200). Diabetes mellitus (DM) remained independently associated with K. pneumoniae isolation in the adjusted model (adjusted OR 1.88; 95% CI [1.01–3.41]; p = 0.045).

Conclusions

While E. coli remains the leading uropathogen, with susceptibility patterns supporting phosphomycin and nitrofurantoin as first-line empirical therapies, DM, rather than SGLT2 inhibitor use, was independently associated with K. pneumoniae isolation. The unadjusted signal observed with SGLT2 inhibitors should be considered an exploratory, hypothesis-generating finding requiring confirmation in larger prospective cohorts.

Zitieren

APA

Ruiz-Ruiz, F., Lobo-Fernández, P., Vivancos-Caro, A., Fernández-Ojeda, M. D. R., Ruiz-Romero, V., Fernández-Moyano, A., Gómez-Morales, L., & García-Sánchez, E. (2026). Community-acquired urinary tract infections in Southern Spain: epidemiology, antimicrobial resistance, and the emerging impact of SGLT2 inhibitors. PeerJ, 14, e21738. https://doi.org/10.7717/peerj.21738

Vancouver

Ruiz-Ruiz F, Lobo-Fernández P, Vivancos-Caro A, Fernández-Ojeda MDR, Ruiz-Romero V, Fernández-Moyano A, et al. Community-acquired urinary tract infections in Southern Spain: epidemiology, antimicrobial resistance, and the emerging impact of SGLT2 inhibitors. PeerJ. 2026;14:e21738. doi:10.7717/peerj.21738

BibTeX
@article{RuizRuiz2026,
  author = {Ruiz-Ruiz, Francisco and Lobo-Fernández, Palma and Vivancos-Caro, Aurora and Fernández-Ojeda, María del Rocío and Ruiz-Romero, Victoria and Fernández-Moyano, Antonio and Gómez-Morales, Luis and García-Sánchez, Estefanía},
  title = {Community-acquired urinary tract infections in Southern Spain: epidemiology, antimicrobial resistance, and the emerging impact of SGLT2 inhibitors},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21738},
  doi = {10.7717/peerj.21738}
}
Kostenlos starten →